CLDN14

Across TCGA pan-cancer cohorts, CLDN14 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLDN14 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher CLDN14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLDN14 expression acts as an unfavorable survival marker.

THCA and LAML are the cancer types where CLDN14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.828	<.001	24	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLDN14–THCA (DFS)

Open the THCA breakdown →